205 related articles for article (PubMed ID: 25500109)
1. Modifiable factors associated with copeptin concentration: a general population cohort.
van Gastel MD; Meijer E; Scheven LE; Struck J; Bakker SJ; Gansevoort RT
Am J Kidney Dis; 2015 May; 65(5):719-27. PubMed ID: 25500109
[TBL] [Abstract][Full Text] [Related]
2. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
[TBL] [Abstract][Full Text] [Related]
3. Comparison between copeptin and vasopressin in a population from the community and in people with chronic kidney disease.
Roussel R; Fezeu L; Marre M; Velho G; Fumeron F; Jungers P; Lantieri O; Balkau B; Bouby N; Bankir L; Bichet DG
J Clin Endocrinol Metab; 2014 Dec; 99(12):4656-63. PubMed ID: 25202818
[TBL] [Abstract][Full Text] [Related]
4. The Vasopressin System in the Risk of Diabetes and Cardiorenal Disease, and Hydration as a Potential Lifestyle Intervention.
Enhörning S; Melander O
Ann Nutr Metab; 2018; 72 Suppl 2():21-27. PubMed ID: 29925066
[TBL] [Abstract][Full Text] [Related]
5. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort.
Meijer E; Bakker SJ; Halbesma N; de Jong PE; Struck J; Gansevoort RT
Kidney Int; 2010 Jan; 77(1):29-36. PubMed ID: 19847155
[TBL] [Abstract][Full Text] [Related]
6. Plasma Copeptin and Decline in Renal Function in a Cohort from the Community: The Prospective D.E.S.I.R. Study.
Roussel R; Matallah N; Bouby N; El Boustany R; Potier L; Fumeron F; Mohammedi K; Balkau B; Marre M; Bankir L; Velho G
Am J Nephrol; 2015; 42(2):107-14. PubMed ID: 26346607
[TBL] [Abstract][Full Text] [Related]
7. An abnormal apelin/vasopressin balance may contribute to water retention in patients with the syndrome of inappropriate antidiuretic hormone (SIADH) and heart failure.
Blanchard A; Steichen O; De Mota N; Curis E; Gauci C; Frank M; Wuerzner G; Kamenicky P; Passeron A; Azizi M; Llorens-Cortes C
J Clin Endocrinol Metab; 2013 May; 98(5):2084-9. PubMed ID: 23515451
[TBL] [Abstract][Full Text] [Related]
8. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.
Boertien WE; Meijer E; Zittema D; van Dijk MA; Rabelink TJ; Breuning MH; Struck J; Bakker SJ; Peters DJ; de Jong PE; Gansevoort RT
Nephrol Dial Transplant; 2012 Nov; 27(11):4131-7. PubMed ID: 22523115
[TBL] [Abstract][Full Text] [Related]
9. Copeptin, a surrogate marker for arginine vasopressin secretion, is associated with higher glucose and insulin concentrations but not higher blood pressure in obese men.
Asferg CL; Andersen UB; Linneberg A; Goetze JP; Jeppesen JL
Diabet Med; 2014 Jun; 31(6):728-32. PubMed ID: 24533694
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in the association between plasma copeptin and incident type 2 diabetes: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
Abbasi A; Corpeleijn E; Meijer E; Postmus D; Gansevoort RT; Gans RO; Struck J; Hillege HL; Stolk RP; Navis G; Bakker SJ
Diabetologia; 2012 Jul; 55(7):1963-70. PubMed ID: 22526609
[TBL] [Abstract][Full Text] [Related]
11. Plasma copeptin, a unifying factor behind the metabolic syndrome.
Enhörning S; Struck J; Wirfält E; Hedblad B; Morgenthaler NG; Melander O
J Clin Endocrinol Metab; 2011 Jul; 96(7):E1065-72. PubMed ID: 21490073
[TBL] [Abstract][Full Text] [Related]
12. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
Nakajima A; Lu Y; Kawano H; Horie S; Muto S
Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
[TBL] [Abstract][Full Text] [Related]
13. Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial.
Sontrop JM; Huang SH; Garg AX; Moist L; House AA; Gallo K; Clark WF
BMJ Open; 2015 Nov; 5(11):e008634. PubMed ID: 26603245
[TBL] [Abstract][Full Text] [Related]
14. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.
Meijer E; Bakker SJ; van der Jagt EJ; Navis G; de Jong PE; Struck J; Gansevoort RT
Clin J Am Soc Nephrol; 2011 Feb; 6(2):361-8. PubMed ID: 20930090
[TBL] [Abstract][Full Text] [Related]
15. Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?
Casteleijn NF; Zittema D; Bakker SJ; Boertien WE; Gaillard CA; Meijer E; Spithoven EM; Struck J; Gansevoort RT
Am J Nephrol; 2015; 41(3):248-56. PubMed ID: 25926129
[TBL] [Abstract][Full Text] [Related]
16. Increased Levels of Copeptin, a Surrogate Marker of Arginine Vasopressin, Are Associated with an Increased Risk of Chronic Kidney Disease in a General Population.
Tasevska I; Enhörning S; Christensson A; Persson M; Nilsson PM; Melander O
Am J Nephrol; 2016; 44(1):22-8. PubMed ID: 27347674
[TBL] [Abstract][Full Text] [Related]
17. Sexual disparity of copeptin in healthy newborn infants.
Burckhardt MA; Wellmann M; Fouzas S; Lapaire O; Burkhardt T; Benzing J; Bührer C; Szinnai G; Wellmann S
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1750-3. PubMed ID: 25004250
[TBL] [Abstract][Full Text] [Related]
18. Association of Copeptin, a Surrogate Marker of Arginine Vasopressin, with Decreased Kidney Function in Sugarcane Workers in Guatemala.
Butler-Dawson J; Dally M; Johnson RJ; Johnson EC; Krisher L; Sánchez-Lozada LG; Griffin BR; Brindley S; Newman LS
Ann Nutr Metab; 2020; 76(1):30-36. PubMed ID: 32172243
[TBL] [Abstract][Full Text] [Related]
19. Gender and renal function influence plasma levels of copeptin in healthy individuals.
Bhandari SS; Loke I; Davies JE; Squire IB; Struck J; Ng LL
Clin Sci (Lond); 2009 Feb; 116(3):257-63. PubMed ID: 18647134
[TBL] [Abstract][Full Text] [Related]
20. Water Supplementation Reduces Copeptin and Plasma Glucose in Adults With High Copeptin: The H2O Metabolism Pilot Study.
Enhörning S; Brunkwall L; Tasevska I; Ericson U; Persson Tholin J; Persson M; Lemetais G; Vanhaecke T; Dolci A; Perrier ET; Melander O
J Clin Endocrinol Metab; 2019 Jun; 104(6):1917-1925. PubMed ID: 30566641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
